CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Sumitomo Pharma's enzomenib shows 57% response rate at 300 mg twice daily in leukemia study

By Public Technologies
  • Sumitomo Pharma America will present enzomenib and nuvisertib clinical data at the American Society of Hematology meeting December 12-15, 2026.
  • Enzomenib presentations will include initial pivotal Phase 2 results in relapsed or refractory acute leukemia with KMT2A rearrangements.
  • A completed enzomenib dose-optimization study showed generally tolerable treatment with clinical activity in relapsed or refractory NPM1-mutated acute leukemia.
  • Preliminary nuvisertib-momelotinib results showed clinical responses and generally tolerable treatment in myelofibrosis, supporting Phase 3 development for patients with anemia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Pharma Co. Ltd. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk